ATE447559T1 - 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen - Google Patents

4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen

Info

Publication number: ATE447559T1
Authority: AT; Austria
Prior art keywords: dihydropyridazine; phenylamino; oxo; treatment; hyperproliferative diseases
Prior art date: 2005-05-18

Application number

AT08004958T

Other languages

English (en)

Inventor

Richard Anthony Storey

Rebecca Jane Booth

John David Pittam

John Leonard

Mark Richard Fielding

Allison L Marlow

Eli M Wallace

Jeongbeob Seo

Joseph P Lyssikatos

Hong Woon Yang

James Blake

Original Assignee

Array Biopharma Inc

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-18

Filing date

2006-05-17

Publication date

2009-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37943261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE447559(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-05-17 Application filed by Array Biopharma Inc, Astrazeneca Ab filed Critical Array Biopharma Inc

2009-11-15 Application granted granted Critical

2009-11-15 Publication of ATE447559T1 publication Critical patent/ATE447559T1/de

Links

FLWCPMUXFYEUMZ-UHFFFAOYSA-N 4-anilino-6-oxo-1h-pyridazine-3-carboxamide Chemical class NC(=O)C1=NNC(=O)C=C1NC1=CC=CC=C1 FLWCPMUXFYEUMZ-UHFFFAOYSA-N 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
230000003463 hyperproliferative effect Effects 0.000 title 1
239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)

AT08004958T 2005-05-18 2006-05-17 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen ATE447559T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US68233505P	2005-05-18	2005-05-18

Publications (1)

Publication Number	Publication Date
ATE447559T1 true ATE447559T1 (de)	2009-11-15

Family

ID=37943261

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT06836069T ATE539064T1 (de)	2005-05-18	2006-05-17	Heterozyklische inhibitoren von mek und verwendungsverfahren damit
AT08004958T ATE447559T1 (de)	2005-05-18	2006-05-17	4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT06836069T ATE539064T1 (de)	2005-05-18	2006-05-17	Heterozyklische inhibitoren von mek und verwendungsverfahren damit

Country Status (32)

Country	Link
US (1)	US8299076B2 (de)
EP (4)	EP1967516B1 (de)
JP (3)	JP5270336B2 (de)
KR (3)	KR20110074772A (de)
CN (5)	CN102898364A (de)
AR (3)	AR055057A1 (de)
AT (2)	ATE539064T1 (de)
AU (1)	AU2006299902B2 (de)
BR (1)	BRPI0610139A2 (de)
CA (1)	CA2608201C (de)
CL (2)	CL2008003486A1 (de)
CY (1)	CY1112297T1 (de)
DE (1)	DE602006010243D1 (de)
DK (1)	DK1922307T3 (de)
EC (1)	ECSP078013A (de)
ES (4)	ES2405785T3 (de)
HR (1)	HRP20120154T1 (de)
IL (3)	IL187353A (de)
MY (2)	MY149960A (de)
NO (1)	NO20076412L (de)
NZ (3)	NZ587190A (de)
PL (3)	PL2361905T3 (de)
PT (2)	PT2361905E (de)
RS (1)	RS52243B (de)
RU (4)	RU2500673C2 (de)
SA (1)	SA06270141B1 (de)
SG (2)	SG177981A1 (de)
SI (1)	SI1922307T1 (de)
TW (3)	TWI441637B (de)
UA (2)	UA93678C2 (de)
WO (1)	WO2007044084A2 (de)
ZA (2)	ZA200710318B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7732616B2 (en)	2003-11-19	2010-06-08	Array Biopharma Inc.	Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) *	2003-11-19	2009-04-14	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
CN1905873A (zh)	2003-11-19	2007-01-31	阵列生物制药公司	Mek的杂环抑制剂及其使用方法
ES2405785T3 (es)	2005-05-18	2013-06-03	Array Biopharma Inc.	Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
BRPI0717374A2 (pt)	2006-10-23	2013-10-29	Takeda Pharmaceutical	Inibidores de mapk/erk quinase
GB0625691D0 (en) *	2006-12-22	2007-01-31	Astrazeneca Ab	Combination product
WO2008120004A1 (en) *	2007-04-02	2008-10-09	Astrazeneca Ab	Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
US20100130519A1 (en) *	2007-04-13	2010-05-27	Stephen Robert Wedge	Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
MX2010004074A (es) *	2007-10-15	2010-07-02	Astrazeneca Ab	Combinacion 059.
ES2456966T3 (es) *	2007-11-12	2014-04-24	Takeda Pharmaceutical Company Limited	Inhibidores de MAPK/ERK cinasa
CN101896227A (zh) *	2007-12-12	2010-11-24	阿斯利康(瑞典)有限公司	包含mek抑制剂和极光激酶抑制剂的组合
US20110105521A1 (en)	2008-07-11	2011-05-05	Novartis Ag	Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
WO2010068738A1 (en)	2008-12-10	2010-06-17	Dana-Farber Cancer Institute, Inc.	Mek mutations conferring resistance to mek inhibitors
CN102448938A (zh) *	2009-03-27	2012-05-09	阿迪生物科学公司	作为mek抑制剂的二氢吡啶磺酰胺和二氢吡啶硫酰胺
CN102020851B (zh)	2009-09-16	2013-10-16	大连路明发光科技股份有限公司	一种光转换柔性高分子材料及其用途
ES2576061T3 (es)	2010-02-25	2016-07-05	Dana-Farber Cancer Institute, Inc.	Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
BR112012022801B8 (pt)	2010-03-09	2019-10-29	Dana Farber Cancer Inst Inc	método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
KR101851518B1 (ko)	2010-09-08	2018-04-23	스미또모 가가꾸 가부시끼가이샤	피리다지논 화합물 및 그 중간체의 제조 방법
CN102020651B (zh)	2010-11-02	2012-07-18	北京赛林泰医药技术有限公司	6-芳基氨基吡啶酮甲酰胺mek抑制剂
EP2655601A4 (de)	2010-12-22	2014-09-10	Fate Therapeutics Inc	Zellkulturplattform für einzelzellsortierung und verbesserte neuprogrammierung von ipscs
FI20115234A0 (fi)	2011-03-08	2011-03-08	Biotie Therapies Corp	Uusia pyridatsinoni- ja pyridoniyhdisteitä
WO2012145503A1 (en)	2011-04-21	2012-10-26	Novartis Ag	Pharmaceutical combinations
CN102358730A (zh) *	2011-08-24	2012-02-22	济南赛文医药技术有限公司	一种小分子mek蛋白激酶抑制剂
KR20140072028A (ko)	2011-08-31	2014-06-12	노파르티스 아게	Pi3k- 및 mek-억제제의 상승작용적 조합물
WO2013109142A1 (en)	2012-01-16	2013-07-25	Stichting Het Nederlands Kanker Instituut	Combined pdk and mapk/erk pathway inhibition in neoplasia
CN103204825B (zh)	2012-01-17	2015-03-04	上海科州药物研发有限公司	作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
GB201201332D0 (en)	2012-01-26	2012-03-14	Imp Innovations Ltd	Method
US20150141470A1 (en)	2012-05-08	2015-05-21	The Broad Institute, Inc.	Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
WO2014085381A1 (en)	2012-11-29	2014-06-05	Novartis Ag	Pharmaceutical combinations
TW201441193A (zh)	2012-12-06	2014-11-01	Kyowa Hakko Kirin Co Ltd	吡啶酮化合物
PT2975030T (pt) *	2013-03-13	2020-09-28	Chugai Pharmaceutical Co Ltd	Derivado de di-hidropiridazina-3,5-diona
WO2014204263A1 (en)	2013-06-20	2014-12-24	The Asan Foundation	Substituted pyridinone compounds as mek inhibitors
WO2015041534A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk in combination with raf/erk/mek
US9629851B2 (en)	2013-09-20	2017-04-25	Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis	ROCK in combination with MAPK pathway
JP6403172B2 (ja) *	2013-10-25	2018-10-10	シャンハイヘンルイファーマスーティカルカンパニーリミテッドＳｈａｎｇｈａｉＨｅｎｇｒｕｉＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用
AU2015206603B9 (en)	2014-01-14	2019-07-18	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
WO2015131080A1 (en) *	2014-02-28	2015-09-03	Nimbus Lakshmi, Inc.	Tyk2 inhibitors and uses thereof
CA2941004A1 (en)	2014-03-04	2015-09-11	Peter Flynn	Improved reprogramming methods and cell culture platforms
WO2015156674A2 (en)	2014-04-10	2015-10-15	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
WO2015178770A1 (en)	2014-05-19	2015-11-26	Stichting Het Nederlands Kanker Instituut	Compositions for cancer treatment
US10023879B2 (en)	2014-06-04	2018-07-17	Fate Therapeutics, Inc.	Minimal volume reprogramming of mononuclear cells
CA2963091A1 (en)	2014-10-06	2016-04-14	Dana-Farber Cancer Institute, Inc.	Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
WO2016123100A1 (en)	2015-01-26	2016-08-04	Fate Therapeutics, Inc.	Methods and compositions for inducing hematopoietic cell differentiation
MA41866A (fr)	2015-03-31	2018-02-06	Massachusetts Gen Hospital	Molécules à auto-assemblage pour l'administration ciblée de médicaments
WO2017037579A1 (en)	2015-08-28	2017-03-09	Novartis Ag	Mdm2 inhibitors and combinations thereof
CN117737124A (zh)	2015-10-16	2024-03-22	菲特治疗公司	用于诱导和维护基态多能性的平台
KR20250141836A (ko)	2015-11-04	2025-09-29	페이트 세러퓨틱스, 인코포레이티드	만능 세포의 유전자 조작
SG11201803145RA (en)	2015-11-04	2018-05-30	Fate Therapeutics Inc	Methods and compositions for inducing hematopoietic cell differentiation
HUE052157T2 (hu) *	2015-11-18	2021-04-28	Fmc Corp	Eljárás olyan köztes termékek szintézisére, amelyek alkalmasak 1,3,4-triazin származékok elkészítésére
SG11201805186VA (en)	2016-01-20	2018-07-30	Fate Therapeutics Inc	Compositions and methods for immune cell modulation in adoptive immunotherapies
JP7653759B2 (ja)	2016-01-20	2025-03-31	フェイトセラピューティクス，インコーポレイテッド	養子免疫療法における免疫細胞調節のための組成物および方法
JP2019507794A (ja) *	2016-03-10	2019-03-22	ルトリスファーマエルティーディー．	皮膚反応を治療するためのｂｒａｆ阻害剤の使用
WO2018092064A1 (en)	2016-11-18	2018-05-24	Novartis Ag	Combinations of mdm2 inhibitors and bcl-xl inhibitors
EP3548049A4 (de)	2016-12-05	2020-07-22	Fate Therapeutics, Inc.	Zusammensetzungen und verfahren zur immunzellmodulation bei adoptiven immuntherapien
KR102435424B1 (ko) *	2017-09-13	2022-08-23	엘지디스플레이 주식회사	듀티 구동 기능을 갖는 표시장치 및 이의 구동방법
EA202192575A1 (ru)	2019-03-21	2022-01-14	Онксео	Соединения dbait в сочетании с ингибиторами киназ для лечения рака
TWI817018B (zh)	2019-06-28	2023-10-01	美商艾瑞生藥股份有限公司	用於治療ｂｒａｆ相關的疾病和失調症之化合物
CN114761006A (zh)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	对激酶抑制剂产生耐药性的癌症的治疗方法
AR121078A1 (es)	2020-01-22	2022-04-13	Chugai Pharmaceutical Co Ltd	Derivados de arilamida con actividad antitumoral
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
TW202426436A (zh)	2020-06-09	2024-07-01	美商艾瑞生藥股份有限公司	用於治療ｂｒａｆ相關的疾病和病症之化合物
TWI825637B (zh)	2021-03-31	2023-12-11	美商輝瑞股份有限公司	啶－１，６（２ｈ，７ｈ）－二酮
US12280055B2 (en)	2021-05-27	2025-04-22	Mirati Therapeutics, Inc.	Combination therapies
US11878958B2 (en)	2022-05-25	2024-01-23	Ikena Oncology, Inc.	MEK inhibitors and uses thereof
WO2025073765A1 (en)	2023-10-03	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3682932A (en)	1970-11-23	1972-08-08	Hoffmann La Roche	2-chloro-6-hydroxynicotinic acid
DE2150772A1 (de)	1971-10-12	1973-04-19	Cassella Farbwerke Mainkur Ag	Verfahren zur herstellung von 6-hydroxy-2-pyridon-3-carbonsaeureamidverbindungen
DE2307169A1 (de)	1973-02-14	1974-09-26	Bayer Ag	Azofarbstoffe
US4851535A (en)	1985-01-23	1989-07-25	Toyama Chemical Co., Ltd.	Nicotinic acid derivatives
AT392789B (de)	1985-01-23	1991-06-10	Toyama Chemical Co Ltd	Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
GB8607683D0 (en)	1986-03-27	1986-04-30	Ici Plc	Anti-tumor agents
GB8827305D0 (en)	1988-11-23	1988-12-29	British Bio Technology	Compounds
FR2687676B1 (fr)	1992-02-24	1994-07-08	Union Pharma Scient Appl	Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5750545A (en)	1993-07-23	1998-05-12	The Green Cross Corporation	Triazole derivative and pharmaceutical use thereof
PT672041E (pt) *	1993-10-01	2002-04-29	Novartis Ag	Derivados da piridina farmacologicamente activos e processos para a sua preparacao
US5525625A (en)	1995-01-24	1996-06-11	Warner-Lambert Company	2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
ES2153031T4 (es)	1995-04-20	2001-05-16	Pfizer	Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
ATE225343T1 (de)	1995-12-20	2002-10-15	Hoffmann La Roche	Matrix-metalloprotease inhibitoren
DE69720965T2 (de)	1996-02-13	2004-02-05	Astrazeneca Ab	Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en)	1996-03-05	2000-03-27	Zeneca Ltd	4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
EP0818442A3 (de)	1996-07-12	1998-12-30	Pfizer Inc.	Cyclische Sulphonderivate als Metalloproteinase-Inhibitoren und zur Hemmung der Produktion von Tumornekrosefaktor
KR20000067904A (ko)	1996-07-18	2000-11-25	디. 제이. 우드, 스피겔 알렌 제이	매트릭스 메탈로프로테아제의 포스피네이트계 억제제
KR20000068248A (ko)	1996-08-23	2000-11-25	디. 제이. 우드, 스피겔 알렌 제이	아릴설포닐아미노 하이드록삼산 유도체
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
JP3338064B2 (ja)	1997-01-06	2002-10-28	ファイザー・インク	環状スルホン誘導体
NZ336840A (en)	1997-02-03	2001-01-26	Pfizer Prod Inc	Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
JP2000507975A (ja)	1997-02-07	2000-06-27	ファイザー・インク	Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
EP0960098A1 (de)	1997-02-11	1999-12-01	Pfizer Inc.	Arylsulphonyl hydroxamsaurederivate
CA2280930C (en)	1997-02-12	2010-04-06	The Regents Of The University Of Michigan	Protein markers for lung cancer and use thereof
UA73073C2 (uk)	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6310060B1 (en)	1998-06-24	2001-10-30	Warner-Lambert Company	2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
NZ501276A (en)	1997-07-01	2000-10-27	Warner Lambert Co	4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
US6506798B1 (en)	1997-07-01	2003-01-14	Warner-Lambert Company	4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
BR9810385A (pt)	1997-07-01	2000-09-05	Warner Lambert Co	Derivados de ácido benzóico 2-(4-bromo ou 4-iodo fenilamino) e sua utilização como inibidores de mek
US6821963B2 (en)	1997-07-01	2004-11-23	Warner-Lambert Company	4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
GB9714249D0 (en)	1997-07-08	1997-09-10	Angiogene Pharm Ltd	Vascular damaging agents
CA2299355C (en)	1997-08-08	2005-09-27	Pfizer Products Inc.	Aryloxyarylsulfonylamino hydroxamic acid derivatives
GB9725782D0 (en)	1997-12-05	1998-02-04	Pfizer Ltd	Therapeutic agents
GB9801690D0 (en)	1998-01-27	1998-03-25	Pfizer Ltd	Therapeutic agents
JP4462654B2 (ja)	1998-03-26	2010-05-12	ソニー株式会社	映像素材選択装置及び映像素材選択方法
PA8469501A1 (es)	1998-04-10	2000-09-29	Pfizer Prod Inc	Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es)	1998-04-10	2000-05-24	Pfizer Prod Inc	Derivados biciclicos del acido hidroxamico
AUPP466598A0 (en)	1998-07-14	1998-08-06	University Of Newcastle Research Associates Limited, The	Product and process
EP1004578B1 (de)	1998-11-05	2004-02-25	Pfizer Products Inc.	5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
WO2000040237A1 (en)	1999-01-07	2000-07-13	Warner-Lambert Company	Antiviral method using mek inhibitors
EP1140062B1 (de)	1999-01-07	2005-04-06	Warner-Lambert Company LLC	Behandlung von asthma anhand von mek-inhibitoren
ATE311363T1 (de)	1999-01-13	2005-12-15	Warner Lambert Co	Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
IL144214A0 (en)	1999-01-13	2002-05-23	Warner Lambert Co	Benzoheterocycles and their use as mek inhibitors
CA2349832A1 (en) *	1999-01-13	2000-07-20	Warner-Lambert Company	Benzenesulfonamide derivatives and their use as mek inhibitors
CA2349180A1 (en)	1999-01-13	2000-07-20	Stephen Douglas Barrett	Anthranilic acid derivatives
DE69926914T2 (de)	1999-01-13	2006-06-29	Warner-Lambert Co. Llc	1-heterozyklus-substituierte diarylaminen
CA2348236A1 (en)	1999-01-13	2000-07-20	Stephen Douglas Barrett	4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
GB9900752D0 (en)	1999-01-15	1999-03-03	Angiogene Pharm Ltd	Benzimidazole vascular damaging agents
PT1154774E (pt)	1999-02-10	2005-10-31	Astrazeneca Ab	Derivados de quinazolina como inibidores de angiogenese
GB9910577D0 (en)	1999-05-08	1999-07-07	Zeneca Ltd	Chemical compounds
KR20020012315A (ko)	1999-07-16	2002-02-15	로즈 암스트롱, 크리스틴 에이. 트러트웨인	Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
PL352835A1 (en)	1999-07-16	2003-09-08	Warner-Lambert Company	Method for treating chronic pain using mek inhibitors
HUP0202381A3 (en)	1999-07-16	2004-12-28	Warner Lambert Co	Method for treating chronic pain using mek inhibitors
ES2208364T3 (es)	1999-07-16	2004-06-16	Warner-Lambert Company Llc	Procedimiento para tratar dolor cronico usando inhibidores de mek.
US7030119B1 (en)	1999-07-16	2006-04-18	Warner-Lambert Company	Method for treating chronic pain using MEK inhibitors
KR100881105B1 (ko)	1999-11-05	2009-02-02	아스트라제네카 아베	Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
JP3663382B2 (ja)	2000-02-15	2005-06-22	スージェン・インコーポレーテッド	ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
EP1339702A1 (de)	2000-03-15	2003-09-03	Warner-Lambert Company	5-amid-substituierte diarylamine als mek inhibitoren
MXPA02008103A (es)	2000-03-15	2002-11-29	Warner Lambert Co	Diarilaminas sustituidas con 5-amida como inhibidores mek.
AU2001258628A1 (en)	2000-05-31	2001-12-11	Astrazeneca Ab	Indole derivatives with vascular damaging activity
MXPA02012905A (es)	2000-07-07	2004-07-30	Angiogene Pharm Ltd	Derivados de colquinol como agentes de dano vascular..
MXPA02012903A (es)	2000-07-07	2004-07-30	Angiogene Pharm Ltd	Derivados de colquinol como inhibidores de angiogenesis.
JP3811775B2 (ja)	2000-07-19	2006-08-23	ワーナー−ランバートカンパニーリミティドライアビリティーカンパニー	４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
RU2167659C1 (ru)	2000-08-02	2001-05-27	Закрытое акционерное общество "Центр современной медицины "Медикор"	Способ коррекции иммунной системы живого организма
SK2072003A3 (en)	2000-08-25	2004-01-08	Warner Lambert Co	Process for making N-aryl-anthranilic acids and their derivatives
US7067532B2 (en)	2000-11-02	2006-06-27	Astrazeneca	Substituted quinolines as antitumor agents
US6642215B2 (en)	2001-05-24	2003-11-04	Leo Pharma A/S	Method of modulating NF-kB activity
US20040039208A1 (en)	2001-07-20	2004-02-26	Chen Michael Huai Gu	Process for making n-aryl-anthranilic acids and their derivatives
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
KR100984595B1 (ko)	2002-03-13	2010-09-30	어레이 바이오파마 인크.	Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
US7235537B2 (en)	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1482944A4 (de)	2002-03-13	2006-04-19	Array Biopharma Inc	N3 alkylierte benzimidazol-derivate als mek-hemmer
EP1487794A1 (de)	2002-03-14	2004-12-22	Bayer Aktiengesellschaft	Monozyklische aroylpyridinone als entzündungshemmende agentien
WO2004000529A1 (de)	2002-06-24	2003-12-31	Fagerdala Deutschland Gmbh	Verfahren zur herstellung von bauteilen aus hochgradig lignocellulosefaser-gefüllten thermoplasten
WO2005000818A1 (en) *	2003-06-27	2005-01-06	Warner-Lambert Company Llc	5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
TW200510425A (en)	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US7144907B2 (en) *	2003-09-03	2006-12-05	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
CN1905873A (zh) *	2003-11-19	2007-01-31	阵列生物制药公司	Mek的杂环抑制剂及其使用方法
US7517994B2 (en)	2003-11-19	2009-04-14	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en)	2003-11-19	2010-06-08	Array Biopharma Inc.	Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
ES2251866B1 (es)	2004-06-18	2007-06-16	Laboratorios Almirall S.A.	Nuevos derivados de piridazin-3(2h)-ona.
ES2405785T3 (es)	2005-05-18	2013-06-03	Array Biopharma Inc.	Inhibidores heterocíclicos de MEK y métodos de uso de los mismos

2006
- 2006-05-17 ES ES11003827T patent/ES2405785T3/es active Active
- 2006-05-17 KR KR1020117011251A patent/KR20110074772A/ko not_active Ceased
- 2006-05-17 US US11/914,433 patent/US8299076B2/en not_active Expired - Fee Related
- 2006-05-17 PT PT110038270T patent/PT2361905E/pt unknown
- 2006-05-17 PL PL11003827T patent/PL2361905T3/pl unknown
- 2006-05-17 UA UAA200712647A patent/UA93678C2/ru unknown
- 2006-05-17 CN CN2012103746556A patent/CN102898364A/zh active Pending
- 2006-05-17 DE DE602006010243T patent/DE602006010243D1/de active Active
- 2006-05-17 SA SA06270141A patent/SA06270141B1/ar unknown
- 2006-05-17 EP EP08004958A patent/EP1967516B1/de active Active
- 2006-05-17 RS RS20120090A patent/RS52243B/sr unknown
- 2006-05-17 EP EP06836069A patent/EP1922307B1/de active Active
- 2006-05-17 UA UAA200904802A patent/UA100007C2/ru unknown
- 2006-05-17 SI SI200631291T patent/SI1922307T1/sl unknown
- 2006-05-17 KR KR1020077029520A patent/KR20080019236A/ko not_active Abandoned
- 2006-05-17 PT PT06836069T patent/PT1922307E/pt unknown
- 2006-05-17 SG SG2012002887A patent/SG177981A1/en unknown
- 2006-05-17 NZ NZ587190A patent/NZ587190A/en not_active IP Right Cessation
- 2006-05-17 CN CN2012103757743A patent/CN102942522A/zh active Pending
- 2006-05-17 ES ES06836069T patent/ES2378760T3/es active Active
- 2006-05-17 ES ES11003826.2T patent/ES2500068T3/es active Active
- 2006-05-17 CN CN2011102242374A patent/CN102304086B/zh not_active Expired - Fee Related
- 2006-05-17 CN CN200680026372A patent/CN101626767A/zh active Pending
- 2006-05-17 AR ARP060101994A patent/AR055057A1/es not_active Application Discontinuation
- 2006-05-17 EP EP11003827A patent/EP2361905B1/de active Active
- 2006-05-17 DK DK06836069.2T patent/DK1922307T3/da active
- 2006-05-17 CN CN201110224236XA patent/CN102321030A/zh active Pending
- 2006-05-17 SG SG201002953-6A patent/SG161318A1/en unknown
- 2006-05-17 MY MYPI2010001331A patent/MY149960A/en unknown
- 2006-05-17 AT AT06836069T patent/ATE539064T1/de active
- 2006-05-17 HR HR20120154T patent/HRP20120154T1/hr unknown
- 2006-05-17 KR KR1020117011249A patent/KR20110074908A/ko not_active Ceased
- 2006-05-17 NZ NZ587189A patent/NZ587189A/en not_active IP Right Cessation
- 2006-05-17 RU RU2009118281/04A patent/RU2500673C2/ru not_active IP Right Cessation
- 2006-05-17 TW TW095117459A patent/TWI441637B/zh not_active IP Right Cessation
- 2006-05-17 TW TW101118140A patent/TW201238952A/zh unknown
- 2006-05-17 CA CA2608201A patent/CA2608201C/en not_active Expired - Fee Related
- 2006-05-17 EP EP11003826.2A patent/EP2364973B1/de active Active
- 2006-05-17 JP JP2008512476A patent/JP5270336B2/ja not_active Expired - Fee Related
- 2006-05-17 WO PCT/US2006/019108 patent/WO2007044084A2/en not_active Ceased
- 2006-05-17 AT AT08004958T patent/ATE447559T1/de not_active IP Right Cessation
- 2006-05-17 ES ES08004958T patent/ES2333182T3/es active Active
- 2006-05-17 NZ NZ563707A patent/NZ563707A/en not_active IP Right Cessation
- 2006-05-17 AU AU2006299902A patent/AU2006299902B2/en not_active Ceased
- 2006-05-17 MY MYPI20062270A patent/MY149957A/en unknown
- 2006-05-17 PL PL06836069T patent/PL1922307T3/pl unknown
- 2006-05-17 TW TW101118139A patent/TWI506020B/zh not_active IP Right Cessation
- 2006-05-17 RU RU2007146115/04A patent/RU2414455C2/ru not_active IP Right Cessation
- 2006-05-17 PL PL11003826T patent/PL2364973T3/pl unknown
- 2006-05-17 BR BRPI0610139-9A patent/BRPI0610139A2/pt not_active IP Right Cessation
2007
- 2007-04-28 ZA ZA2007/10318A patent/ZA200710318B/en unknown
- 2007-11-13 IL IL187353A patent/IL187353A/en not_active IP Right Cessation
- 2007-12-12 NO NO20076412A patent/NO20076412L/no not_active Application Discontinuation
- 2007-12-13 EC EC2007008013A patent/ECSP078013A/es unknown
2008
- 2008-11-21 CL CL2008003486A patent/CL2008003486A1/es unknown
2009
- 2009-05-19 JP JP2009120619A patent/JP5089649B2/ja not_active Expired - Fee Related
- 2009-10-23 CL CL2009001993A patent/CL2009001993A1/es unknown
2010
- 2010-07-12 RU RU2010128512/04A patent/RU2010128512A/ru not_active Application Discontinuation
- 2010-11-02 RU RU2010144823/04A patent/RU2010144823A/ru not_active Application Discontinuation
2011
- 2011-04-14 IL IL212396A patent/IL212396A/en not_active IP Right Cessation
- 2011-04-14 IL IL212398A patent/IL212398A/en not_active IP Right Cessation
- 2011-08-31 AR ARP110103182A patent/AR082826A2/es not_active Application Discontinuation
- 2011-08-31 AR ARP110103181A patent/AR082825A2/es not_active Application Discontinuation
2012
- 2012-01-31 CY CY20121100105T patent/CY1112297T1/el unknown
- 2012-05-25 ZA ZA2012/03844A patent/ZA201203844B/en unknown
- 2012-10-03 JP JP2012220857A patent/JP5576919B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
TW201302708A (zh)	2013-01-16
CA2608201A1 (en)	2007-04-19
WO2007044084A2 (en)	2007-04-19
CL2008003486A1 (es)	2009-03-20
TW200714590A (en)	2007-04-16
CA2608201C (en)	2013-12-31
ECSP078013A (es)	2008-04-28
HK1121140A1 (en)	2009-04-17
SG177981A1 (en)	2012-02-28
TWI506020B (zh)	2015-11-01
ATE539064T1 (de)	2012-01-15
AU2006299902B2 (en)	2012-11-01
AR055057A1 (es)	2007-08-01
IL212398A0 (en)	2011-06-30
PL2361905T3 (pl)	2013-07-31
AR082825A2 (es)	2013-01-09
MY149960A (en)	2013-11-15
IL187353A0 (en)	2008-04-13
CN102304086A (zh)	2012-01-04
ES2405785T3 (es)	2013-06-03
EP2364973B1 (de)	2014-07-09
PT1922307E (pt)	2012-01-25
IL212398A (en)	2014-09-30
EP2361905B1 (de)	2013-03-06
NZ587189A (en)	2011-11-25
MY149957A (en)	2013-11-15
UA100007C2 (ru)	2012-11-12
SA06270141B1 (ar)	2009-11-15
EP1967516B1 (de)	2009-11-04
RU2414455C2 (ru)	2011-03-20
DK1922307T3 (da)	2012-04-02
TWI441637B (zh)	2014-06-21
RU2010128512A (ru)	2012-01-20
US20080280957A1 (en)	2008-11-13
EP1922307A4 (de)	2009-12-30
CN102304086B (zh)	2013-12-04
RU2500673C2 (ru)	2013-12-10
SI1922307T1 (de)	2012-04-30
HK1124048A1 (en)	2009-07-03
ES2500068T3 (es)	2014-09-30
KR20110074908A (ko)	2011-07-04
RS52243B (sr)	2012-10-31
US8299076B2 (en)	2012-10-30
IL212396A (en)	2015-09-24
AR082826A2 (es)	2013-01-09
JP5270336B2 (ja)	2013-08-21
KR20110074772A (ko)	2011-07-01
BRPI0610139A2 (pt)	2010-06-01
RU2009118281A (ru)	2010-11-20
JP2008545654A (ja)	2008-12-18
NZ587190A (en)	2011-11-25
CY1112297T1 (el)	2015-12-09
TW201238952A (en)	2012-10-01
RU2007146115A (ru)	2009-06-27
DE602006010243D1 (de)	2009-12-17
JP2013028637A (ja)	2013-02-07
JP5089649B2 (ja)	2012-12-05
JP2009215312A (ja)	2009-09-24
EP1922307A2 (de)	2008-05-21
CN101626767A (zh)	2010-01-13
NZ563707A (en)	2011-01-28
ZA201203844B (en)	2014-02-26
AU2006299902A1 (en)	2007-04-19
PL2364973T3 (pl)	2014-12-31
HRP20120154T1 (hr)	2012-03-31
JP5576919B2 (ja)	2014-08-20
IL212396A0 (en)	2011-06-30
PT2361905E (pt)	2013-03-18
SG161318A1 (en)	2010-05-27
EP1922307B1 (de)	2011-12-28
CN102321030A (zh)	2012-01-18
HK1161250A1 (en)	2012-08-24
UA93678C2 (ru)	2011-03-10
ZA200710318B (en)	2012-09-26
HK1162028A1 (en)	2012-08-17
CL2009001993A1 (es)	2010-06-11
RU2010144823A (ru)	2012-05-10
ES2378760T3 (es)	2012-04-17
WO2007044084A3 (en)	2009-04-16
CN102898364A (zh)	2013-01-30
IL187353A (en)	2013-02-28
EP1967516A1 (de)	2008-09-10
EP2361905A1 (de)	2011-08-31
PL1922307T3 (pl)	2012-07-31
EP2364973A1 (de)	2011-09-14
NO20076412L (no)	2008-01-14
CN102942522A (zh)	2013-02-27
KR20080019236A (ko)	2008-03-03
ES2333182T3 (es)	2010-02-17

Legal Events

Date	Code	Title	Description
2010-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE447559T1 (de)	2009-11-15	4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen
ATE501721T1 (de)	2011-04-15	Chinolin-derivate zur behandlung von latenter tuberkulose
DE602005005810D1 (de)	2008-05-15	Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
NO20083002L (no)	2008-08-14	Fremgangsmate for anvendelse av CD40-bindende forbindelser
ATE527241T1 (de)	2011-10-15	Pyridiazinonderivate zur behandlung von tumoren
EA200971077A1 (ru)	2010-04-30	Гетероциклические модуляторы киназы
EA200801291A1 (ru)	2008-12-30	Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
UA101478C2 (ru)	2013-04-10	Соединения, полезные как ингибиторы raf-киназы
ATE541845T1 (de)	2012-02-15	2,3-substituierte azaindolderivate zur behandlung von virusinfektionen
UA102251C2 (ru)	2013-06-25	Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
EA201270535A1 (ru)	2012-09-28	Пуриновые производные, применимые в качестве ингибиторов hsp90
EA200900798A1 (ru)	2010-10-29	Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
ATE406351T1 (de)	2008-09-15	Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
MX2012002542A (es)	2012-04-02	Compuestos y composiciones como inhibidores de cinasa de proteina.
ATE451363T1 (de)	2009-12-15	3-(indazol-5-yl)-(1,2,4)triazinderivate und verwandte verbindungen als proteinkinaseinhibitoren zur behandlung von krebs
EA200701396A1 (ru)	2007-12-28	Триазолофталазины в качестве ингибиторов pde-2
DE602006017980D1 (de)	2010-12-16	3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
DE602006019468D1 (de)	2011-02-17	Diarylharnstoffe zur behandlung von pulmonaler hypertonie
EA201170344A1 (ru)	2011-08-30	Азаиндольные ингибиторы iap
ATE428417T1 (de)	2009-05-15	Derivate von piperidinylalkylcarbamaten, herstellungsverfahren davon und verwendung derselben als faah-enzym-inhibitoren
EA200601568A1 (ru)	2007-02-27	Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
EA201170828A1 (ru)	2011-12-30	Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза
EP1965827A4 (de)	2009-12-23	Behandlung von entmyelinisierenden erkrankungen
ATE548035T1 (de)	2012-03-15	Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
WO2009015369A3 (en)	2009-12-10	Isophthalamide derivatives inhibiting beta-secretase activity